Sofinnova Investments, Inc. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001631134
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 68 positions · Total reported value $1.77B · Top-10 concentration 52.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 67.1% · 13 new · 16 cut · 26 exited
Active Share (vs S&P 500): 99.1% · vs QQQ: 98.7% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $2.38B — last quarter positions weighted by this quarter price moves · ranking
In its Q1 2024 13F filing, Sofinnova Investments, Inc. disclosed 68 equity positions with a combined reported value of $1.77B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were NTRA ($141.79M), VERA ($120.48M), ASND ($113.99M). By sector, the heaviest allocations are Health Care 80.4%, Industrials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+26.9pp) and away from Consumer Discretionary (-1.5pp), Other (-25.8pp).
Versus the prior quarter, Sofinnova Investments, Inc. opened 13 new positions, trimmed 16 and fully exited 26, a turnover rate of 67.1% of positions. The portfolio's overlap with the prior quarter was 44% of names.
The largest new positions opened in Q1 2024 were XBI ($80.66M), NVO ($78.57M), IDXX ($40.62M).
Of the 26 positions fully exited versus the prior quarter, the largest were KRTX ($437.15M), RYZB ($150.42M), IMGN ($45.87M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
- XBI SPDR SERIES TRUST · $80.66M
- NVO NOVO-NORDISK A S · $78.57M
- IDXX IDEXX LABS INC · $40.62M
- ALGN ALIGN TECHNOLOGY INC · $31.31M
- AVBP ARRIVENT BIOPHARMA INC COM · $30.30M
- TGTX TG THERAPEUTICS · $30.19M
- SRPT SAREPTA THERAPEUTICS INC · $29.45M
- SILK SILK RD MED INC · $21.78M
Fully Exited (vs previous quarter)
- KRTX KARUNA THERAPEUTICS INC · prev qtr: $437.15M
- RYZB RAYZEBIO INC · prev qtr: $150.42M
- IMGN IMMUNOGEN INC · prev qtr: $45.87M
- LLY ELI LILLY & CO · prev qtr: $37.61M
- CYTK CYTOKINETICS INC · prev qtr: $34.58M
- CBAY CYMABAY THERAPEUTICS INC · prev qtr: $33.35M
- SNY SANOFI SA · prev qtr: $29.79M
- KVUE KENVUE INC · prev qtr: $25.99M
Insider Transactions (Form 4)
Latest Sofinnova Investments, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Sofinnova Investments, Inc., based in Menlo Park, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 56 positions worth $1.88B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: MENLO PARK, CA, United States
- SEC registration: 801-110134 (status: Approved), registered 2017-03-22
- Regulatory AUM (Form ADV): $5.37B as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 7 private funds, of which 3 hedge funds
- Website: sofinnova.com
Portfolio Structure
- 56 positions · $1.88B reported value (Q2 2026)
- Top 10 holdings = 59.2% of reported value
- Largest position: NTRA (NATERA INC) at 22.4%
- Average position size: $33.52M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 13 new, 14 added, 16 reduced, 26 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.55M | $141.79M | 8.00% | Hold | |
| 2 |
|
2.79M | $120.48M | 6.80% | Reduce | |
| 3 |
|
754.03K | $113.99M | 6.43% | Hold | |
| 4 |
|
3.76M | $111.14M | 6.27% | Hold | |
| 5 |
|
651.30K | $85.94M | 4.85% | Reduce | |
| 6 |
|
850.00K | $80.66M | 4.55% | New | |
| 7 |
|
611.88K | $78.57M | 4.43% | New | |
| 8 |
|
1.33M | $75.61M | 4.27% | Add | |
| 9 |
|
149.30K | $58.78M | 3.32% | Add | |
| 10 |
|
140.88K | $56.22M | 3.17% | Add | |
| 11 |
|
1.94M | $54.98M | 3.10% | Add | |
| 12 |
|
1.30M | $45.54M | 2.57% | Add | |
| 13 |
|
2.56M | $41.60M | 2.35% | Add | |
| 14 |
|
75.22K | $40.62M | 2.29% | New | |
| 15 |
|
596.71K | $40.43M | 2.28% | Reduce | |
| 16 |
|
1.61M | $38.28M | 2.16% | Add | |
| 17 |
|
220.20K | $37.74M | 2.13% | Add | |
| 18 |
|
2.19M | $35.68M | 2.01% | Hold | |
| 19 |
|
781.60K | $34.30M | 1.94% | Reduce | |
| 20 |
|
801.78K | $33.65M | 1.90% | Reduce | |
| 21 |
|
4.28M | $32.79M | 1.85% | Hold | |
| 22 |
|
95.48K | $31.31M | 1.77% | New | |
| 23 |
|
1.70M | $30.30M | 1.71% | New | |
| 24 |
|
1.98M | $30.19M | 1.70% | New | |
| 25 |
|
227.49K | $29.45M | 1.66% | New | |
| 26 |
|
353.85K | $24.24M | 1.37% | Add | |
| 27 |
|
2.16M | $22.74M | 1.28% | Reduce | |
| 28 |
|
1.19M | $21.78M | 1.23% | New | |
| 29 |
|
2.40M | $16.13M | 0.91% | New | |
| 30 |
|
229.48K | $15.85M | 0.89% | New | |
| 31 |
|
103.04K | $15.40M | 0.87% | New | |
| 32 |
|
594.40K | $14.67M | 0.83% | New | |
| 33 |
|
584.67K | $13.51M | 0.76% | Add | |
| 34 |
|
2.35M | $11.69M | 0.66% | Reduce | |
| 35 |
|
35.00K | $11.40M | 0.64% | New | |
| 36 |
|
501.94K | $10.71M | 0.60% | Reduce | |
| 37 |
|
1.00M | $10.56M | 0.60% | New | |
| 38 |
|
149.38K | $10.30M | 0.58% | New | |
| 39 |
|
854.70K | $7.73M | 0.44% | Add | |
| 40 |
|
503.62K | $7.40M | 0.42% | Add | |
| 41 |
|
429.75K | $7.33M | 0.41% | Hold | |
| 42 |
|
141.16K | $7.19M | 0.41% | Add | |
| 43 |
|
1.52M | $6.90M | 0.39% | New | |
| 44 |
|
150.78K | $6.45M | 0.36% | Add | |
| 45 |
|
198.19K | $6.31M | 0.36% | New | |
| 46 |
|
2.67M | $5.96M | 0.34% | Hold | |
| 47 |
|
232.45K | $5.94M | 0.34% | New | |
| 48 |
|
19.03K | $5.08M | 0.29% | New | |
| 49 |
|
2.75M | $3.86M | 0.22% | Hold | |
| 50 |
|
157.17K | $3.35M | 0.19% | Add | |
FAQ
What did Sofinnova Investments, Inc. buy in 2024-Q1?
In its 2024-Q1 13F filing, Sofinnova Investments, Inc. reported 68 equity positions worth $1.77B in aggregate; its largest disclosed positions were NTRA ($141.79M), VERA ($120.48M), ASND ($113.99M).
How large is Sofinnova Investments, Inc.'s portfolio?
Sofinnova Investments, Inc. reported $1.77B of long equity holdings across 68 positions as of 2024-Q1. Top-10 holdings account for 52.1% of reported value.
What is Sofinnova Investments, Inc.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.